Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Manufacturing of Eyevensys’ Core Ocular Device and Electrical Pulse Generator Technology Covered under a New Collaboration

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology.

Recommended AI News: Cyberdyne Tech Exchange Resolves COP Challenge Through Release of Carbon Neutrality Token (CNT)

#Eyevensys is delighted to embark on the development of a new generation of system devices with the collaboration of US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical.

Eyevensys has developed a non-viral gene therapy ocular drug delivery platform with a proprietary Electrotransfection System designed to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle and sustainably treat major eye diseases. Both components of the Electrotransfection System, the electrical pulse generator and the ocular device, are included in the multi-year engagements established with Eyevensys.

Eyevensys has embarked on the development of a new generation of system devices focusing on optimizing their ease-of-use and manufacturability. Phillips-Medisize will be responsible for Ocular Device design optimization and the high-volume manufacturing capability to support the commercial launch, and Minnetronix Medical will fulfill the same responsibilities for the Pulse Generator component. Work at both contract manufacturers has been initiated.

Alan Wirbisky, Director of Device Development at Eyevensys, said: “The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess. As we look to transition our attention to our other programs for wet AMD, geographic atrophy, retinitis pigmentosa and glaucoma, we are thrilled to have the support of these outstanding cohorts. We’re also grateful for the longtime support of our two French manufacturing partners – Cisteo Medical, Besancon, France the developer and manufacturer of the current generation Ocular Devices as well as Valotec, Villejuif, France developer of the current Pulse Generator. Both companies have been instrumental in Eyevensys achieving its early goals.”

Recommended AI News: Abris-backed Global Technical Group Acquires Lummetry.AI

Benjamin Austin, Director of Business Development at Minnetronix Medical, said: “We are beyond excited to partner with Eyevensys to help bring their next-generation Pulse Generator to market. During our 25 year history, we have successfully partnered with many medical startups like Eyevensys to navigate the pitfalls of electromechanical medical device development. The project team will be comprised of medical device engineers who specialize in electroporation, RF, and stimulator generator development as their core competencies.”

Paul Chaffin, President of Phillips-Medisize, said: “At Phillips-Medisize, we create solutions to help people live healthier, more productive lives and Eyevensys proprietary Electrotransfection System has the potential to do just that. We are honored to bring our decades of design and manufacturing experience to optimize the Ocular Device component for mass production. Phillips-Medisize brings a team with proven expertise in end-to-end design with a focus on quality, risk management, and scalability that will mutually benefit this promising collaboration.”

Recommended AI News: TrialCard Selects Infinitus Systems To Automate Payer Contact Center Activity

[To share your insights with us, please write to sghosh@martechseries.com ]